ÁMÁdám Menus

Ádám Menus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ádám Menus has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Katalin Monostory

    Institute of Molecular Life Sciences HUN‐REN Research Centre for Natural Sciences Budapest Hungary

    4 shared publications
  • Ádám Kiss

    Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest

    4 shared publications
  • Ales Belic

    University of Ljubljana, Ljubljana, Slovenia

    3 shared publications
  • Dávid Sirok

    Research Centre for Natural Sciences, Institute of Enzymology, Hungarian Academy of Sciences, Magyar Tudósok 2, Budapest, 1117, Hungary

    3 shared publications
  • Gábor Csukly

    Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary

    3 shared publications
  • Katalin Tóth

    Research Centre for Natural Sciences, Institute of Enzymology, Hungarian Academy of Sciences, Magyar Tudósok 2, Budapest, 1117, Hungary

    3 shared publications

Latest Publications

  • Association of propranolol with treatment-emergent akathisia during aripiprazole treatment

    by Ádám Menus, Ádám Kiss, Gábor Csukly, István Bitter, Katalin Monostory, János M. Réthely

    Background and purpose – Akathisia is a common side effect of aripiprazole treatment, which is associated with subjective distress for patients, and represents a frequent cause of treatment discontinuation. Propranolol and other beta-receptor blockers are commonly used for treatment of akathisia. Cytochrome P450 2D6 (CYP2D6) enzyme plays a major role in the metabolism of aripiprazole. Our previous study has shown that CYP2D6 inhibitory activity of beta-blockers (metoprolol and propranolol) may result in elevated aripiprazole plasma concentrations. The objective of the present retrospective study was to assess the prevalence of akathisia in patients receiving propranolol or metoprolol comedication, as well as in those not receiving any CYP2D6 inhibitors such as propranolol, metoprolol, risperidone. Methods – Using the data of our previous pharmacogenetic study involving 67 patients diagnosed with schizophrenia or schizoaffective disorder and receiving aripiprazole treatment, we retrospectively investigated the emergence of akathisia within 6 months following aripiprazole initiation. Information on the onset of akathisia was obtained from patients’ medical records. The effects of CYP2D6 genotype, aripiprazole plasma concentration, propranolol and metoprolol comedication on the development of akathisia were analysed. The included patients had already been taking propranolol and metoprolol comedication prior to the initiation of aripiprazole and not for the treatment of akathisia. Results – Schizophrenia and schizoaffective disorder patients treated with propranolol had a significantly higher incidence of documented akathisia (38,5%) compared to the group not receiving CYP2D6 inhibitors (5.9%), and the group treated with metoprolol comedication (7.1%). Among the CYP2D6 inhibitors, only the administration of propranolol increased the risk of akathisia (Wald Chi2=5.5, p=0.02, OR=7.6 [95% CI=1.4-41.4]). The polymorphic CYP2D6 alleles resulting in low CYP2D6 function showed a statistical trend-level association with the occurrence of akathisia (Wald Chi2=2.6, p=0.11, OR=4.7 [95% CI=0.7-30.8]). In a subsequent analysis, we investigated the possible interaction of propranolol and CYP2D6 genotypes on the development of akathisia. The interaction model showed that the effect of propranolol was not dependent on CYP2D6 genotype (Wald Chi2=0.1, p=0.92), however, its independent effect remained significant (Wald Chi2=4.4, p=0.04). Conclusion – Our findings suggest that propranolol comedication increases the risk of the development of akathisia during aripiprazole treatment. It is of paramount importance to avoid propranolol comedication during aripiprazole treatment. However, two major limitations should be considered: akathisia was not assessed using a standardized clinical rating scale, and the majority of patients (80.6%) received antipsychotic combination therapy, which may have influenced the findings. Further prospective studies are needed to confirm these findings based on retrospective, naturalistic analysis about the development of aripiprazole-induced akathisia.

  • Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure

    by Ádám Kiss, Ádám Menus, Katalin Tóth, Máté Déri, Dávid Sirok, Evelyn Gabri, Ales Belic, Gábor Csukly, István Bitter, Katalin Monostory

    The efficacy of aripiprazole therapy and the risk of adverse reactions are influenced by substantial inter-individual variability in aripiprazole metabolizing capacity. In vitro studies assigned the potential role in aripiprazole metabolism to CYP2D6 and CYP3A enzymes; therefore, the association between the steady-state aripiprazole plasma concentrations and patients’ CYP2D6 and CYP3A statuses (CYP2D6, CYP3A4, and CYP3A5 genotypes, and CYP3A4 expression) and/or co-medication with CYP function modifying medications has been investigated in 93 psychiatric patients on stable aripiprazole therapy. The patients’ CYP2D6 genotype had a major effect on aripiprazole plasma concentrations, whereas contribution of CYP3A genotypes and CYP3A4 expression to aripiprazole clearance were considered to be minor or negligible. The role of CYP3A4 expression in aripiprazole metabolism did not predominate even in the patients with nonfunctional CYP2D6 alleles. Furthermore, dehydroaripiprazole exposure was also CYP2D6 genotype-dependent. Dehydroaripiprazole concentrations were comparable with aripiprazole levels in patients with functional CYP2D6 alleles, and 35% or 22% of aripiprazole concentrations in patients with one or two non-functional CYP2D6 alleles, respectively. The concomitant intake of CYP2D6 inhibitors, risperidone, metoprolol, or propranolol was found to increase aripiprazole concentrations in patients with at least one wild-type CYP2D6*1 allele. Risperidone and 9-hydroxy-risperidone inhibited both dehydrogenation and hydroxylation of aripiprazole, whereas metoprolol and propranolol blocked merely the formation of the active dehydroaripiprazole metabolite, switching towards the inactivation pathways. Patients’ CYP2D6 genotype and co-medication with CYP2D6 inhibitors can be considered to be the major determinants of aripiprazole pharmacokinetics. Taking into account CYP2D6 genotype and co-medication with CYP2D6 inhibitors may improve the outcomes of aripiprazole therapy.


  • Open Access

    Potential Role of Patients’ CYP3A-Status in Clozapine Pharmacokinetics

    by Katalin Tóth, Gábor Csukly, Dávid Sirok, Ales Belic, Ádám Kiss, Edit Háfra, Máté Déri, Ádám Menus, István Bitter, Katalin Monostory

    The atypical antipsychotic clozapine is effective in treatment-resistant schizophrenia; however, the success or failure of clozapine therapy is substantially affected by the variables that impact the clozapine blood concentration. Thus, elucidating the inter-individual differences in clozapine pharmacokinetics can facilitate the personalized therapy. Since a potential role in clozapine metabolism is assigned to CYP1A2, CYP2C19, CYP2D6 and CYP3A enzymes, the association between the patients’ CYP status (CYP genotypes, CYP expression) and clozapine clearance was evaluated in 92 psychiatric patients. The patients’ CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine serum concentration, whereas CYP3A4 expression significantly influenced the normalized clozapine concentration (185.53±56.53 in low expressers vs 78.05±29.57 or 66.52±0.25 (ng/mL)/(mg/kg) in normal or high expressers, P<.0001), in particular that the patients expressed CYP1A2 at a relatively low level. The functional CYP3A5*1 allele seemed to influence clozapine concentrations in those patients who expressed CYP3A4 at low levels. The dose requirement for the therapeutic concentration of clozapine was substantially lower in low CYP3A4 expresser patients than in normal/high expressers (2.18±0.64 vs 4.98±1.40 mg/kg, P<.0001). Furthermore, significantly higher plasma concentration ratios of norclozapine/clozapine and clozapine N-oxide/clozapine were observed in the patients displaying normal/high CYP3A4 expression than in the low expressers. Prospective assaying of CYP3A-status (CYP3A4 expression, CYP3A5 genotype) may better identify the patients with higher risk of inefficiency or adverse reactions and may facilitate the improvement of personalized clozapine therapy; however, further clinical studies are required to prove the benefit of CYP3A testing for patients under clozapine therapy.


  • Open Access

    Optimization of Clonazepam Therapy Adjusted to Patient’s CYP3A Status andNAT2Genotype

    by Katalin Tóth, Gábor Csukly, Dávid Sirok, Ales Belic, Ádám Kiss, Edit Háfra, Máté Déri, Ádám Menus, István Bitter, Katalin Monostory

    The shortcomings of clonazepam therapy include tolerance, withdrawal symptoms, and adverse effects such as drowsiness, dizziness, and confusion leading to increased risk of falls. Inter-individual variability in the incidence of adverse events in patients partly originates from the differences in clonazepam metabolism due to genetic and nongenetic factors. Since the prominent role in clonazepam nitro-reduction and acetylation of 7-amino-clonazepam is assigned to CYP3A and N-acetyl transferase 2 enzymes, respectively, the association between the patients’ CYP3A status (CYP3A5 genotype, CYP3A4 expression) or N-acetyl transferase 2 acetylator phenotype and clonazepam metabolism (plasma concentrations of clonazepam and 7-amino-clonazepam) was evaluated in 98 psychiatric patients suffering from schizophrenia or bipolar disorders. The patients’ CYP3A4 expression was found to be the major determinant of clonazepam plasma concentrations normalized by the dose and bodyweight (1263.5±482.9 and 558.5±202.4ng/mL per mg/kg bodyweight in low and normal expressers, respectively, P<.0001). Consequently, the dose requirement for the therapeutic concentration of clonazepam was substantially lower in low-CYP3A4 expresser patients than in normal expressers (0.029±0.011 vs 0.058±0.024mg/kg bodyweight, P<.0001). Furthermore, significantly higher (about 2-fold) plasma concentration ratio of 7-amino-clonazepam and clonazepam was observed in the patients displaying normal CYP3A4 expression and slower N-acetylation than all the others. Prospective assaying of CYP3A4 expression and N-acetyl transferase 2 acetylator phenotype can better identify the patients with higher risk of adverse reactions and can facilitate the improvement of personalized clonazepam therapy and withdrawal regimen.